Gynecologic Cancers: Case 2 - Episode 5
Dr. Monk cites a recent phase II study presented at European Society for Medical Oncology (ESMO) adding cediranib, an oral anti-VEGF tyrosine-kinase inhibitor (TKI), to chemotherapy, which showed promising results.
CASE 2: Cervical Cancer
Stephanie M. is a 48-year-old Caucasian mother of 2 children who works as a dental hygienist.
She presented to her PCP in May 2012 with vaginal discharge and pain during intercourse. Prior medical history was notable for smoking (quit 3 years ago) and well-controlled hypertension. Patient had completed only sporadic cervical screening for the past 10 years.
In September 2014, she presented with worsening abdominal pain and fatigue. CT scan showed diffuse pelvic and aortic adenopathy consistent with disease recurrence. Her renal and hepatic function were adequate.